Apellis Pharmaceuticals Inc. (APLS) Financial Statements (2024 and earlier)

Company Profile

Business Address 100 FIFTH AVENUE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments551,801700,550877,648351,985176,268175,644
Cash and cash equivalents551,801640,192565,779351,985176,268175,644
Short-term investments  60,358311,869   
Restricted cash and investments1,2731,5631,266   
Receivables7,72710,103    
Inventory, net of allowances, customer advances and progress billings85,71416,286    
Inventory85,71416,286    
Prepaid expense36,35024,86811,40019,80224,3345,060
Other current assets36,65870,67726,8781,30836415
Other undisclosed current assets     1,4741,297
Total current assets:719,523824,047917,192373,095202,439182,015
Noncurrent Assets
Operating lease, right-of-use asset18,74719,90117,71914,110
Property, plant and equipment6,1486,1776,8031,655  
Other noncurrent assets15,79931,64018,8553851,094116
Total noncurrent assets:40,69457,71843,37716,1501,094116
TOTAL ASSETS:760,217881,765960,569389,245203,534182,131
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities132,481120,148120,41263,14315,3586,554
Accounts payable37,34216,9098,4778,36110,2553,663
Accrued liabilities95,139103,239111,93554,7835,1032,891
Debt    2,6091,667 
Other undisclosed current liabilities35,12911,6997,915   
Total current liabilities:167,610131,847128,32765,75317,0256,554
Noncurrent Liabilities
Long-term debt and lease obligation92,736206,105374,047154,42318,72219,807
Long-term debt, excluding current maturities92,736189,024358,830142,56718,72219,807
Liabilities, other than long-term debt14,352   6,6556,583
Due to related parties    6,6556,583
Other liabilities      
Operating lease, liability14,35217,08115,21711,857
Other undisclosed noncurrent liabilities315,647328,070238,421134,839159244
Total noncurrent liabilities:422,735551,256627,685289,26225,53626,635
Total liabilities:590,345683,103756,012355,01542,56133,189
Equity
Equity, attributable to parent169,872198,662204,55734,230160,973148,943
Common stock11108665
Additional paid in capital2,479,5961,857,4301,131,013615,850437,856298,201
Accumulated other comprehensive loss(875)(2,090)(117)(154)(123) 
Accumulated deficit(2,308,860)(1,656,688)(926,347)(581,472)(276,766)(149,264)
Total equity:169,872198,662204,55734,230160,973148,943
TOTAL LIABILITIES AND EQUITY:760,217881,765960,569389,245203,534182,131

Income Statement (P&L) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues75,42266,563250,646   
Cost of revenue
(Cost of Goods and Services Sold)
      
Gross profit:75,42266,563250,646   
Operating expenses(670,035)(602,840)(464,372)(288,015)(127,925)(50,767)
Other undisclosed operating income      
Operating loss:(594,613)(536,277)(213,726)(288,015)(127,925)(50,767)
Nonoperating income8,6261,7803,6634,9332,85012
Investment income, nonoperating8,9144184,1645,1092,961 
Other nonoperating income (expense)(288)1,362(501)(175)(111)12
Interest and debt expense    (1,501)  
Other undisclosed loss from continuing operations before equity method investments, income taxes   (132,966)(20,124)  
Loss from continuing operations before equity method investments, income taxes:(585,987)(534,497)(343,029)(304,707)(125,075)(50,755)
Other undisclosed loss from continuing operations before income taxes(65,516)(211,505)    
Loss from continuing operations before income taxes:(651,503)(746,002)(343,029)(304,707)(125,075)(50,755)
Income tax expense(669)(352)(1,845)   
Loss from continuing operations:(652,172)(746,354)(344,874)(304,707)(125,075)(50,755)
Loss before gain (loss) on sale of properties:(746,354)(344,874)(304,707)(125,075)(50,755)
Other undisclosed net loss     (2,427) 
Net loss:(652,172)(746,354)(344,874)(304,707)(127,502)(50,755)
Other undisclosed net loss attributable to parent      (251)
Net loss available to common stockholders, diluted:(652,172)(746,354)(344,874)(304,707)(127,502)(51,006)

Comprehensive Income ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(652,172)(746,354)(344,874)(304,707)(127,502)(50,755)
Other comprehensive income   37   
Comprehensive loss:(652,172)(746,354)(344,837)(304,707)(127,502)(50,755)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,215(1,973) (31)(123) 
Comprehensive loss, net of tax, attributable to parent:(650,957)(748,327)(344,837)(304,738)(127,625)(50,755)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: